| Name | Title | Contact Details |
|---|
VersusGame is a global entertainment pop culture gaming app where users can put money on trending topics about celebrities, pop culture, sports, entertainment, food, and more. This app is the first of its kind to bring power to the masses and allow consumers to capitalize on their knowledge of mainstream culture. Since its launch in 2019, VersusGame has grown significantly, with over $17 Million in cash prizes to more than 9.5 million players.
We offer a range of IT consulting services, all designed to help your company reach its potential. Whether youre looking for a small tweak or complete overhaul, we have you covered. Our services are available a la carte so you can get precisely what y...
Infocyte delivers free self-service threat assessments, advanced endpoint threat detection, incident response, and Microsoft 365 security.
Zyper helps brands identify their top 1% of fans. We dont find influencers, and its more than just content creation: Zyper creates a network of your most passionate users. Find out what Zyper can do for your brand.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.